PTOL-413A (08-03)
Approved for use through 07/31/2006, OMB 0651-0631
U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Tentative Participants: (1) Comb Billing (2)		Applica	nt Initiated Inte	rview Request	Form	
Issues (Rej., Obj., etc) Fig. #s Art (1) Rej. 1-26	Tentative Particips (1) Charles Billing (3) Proposed Date of Interview I (1) Telephonic Exhibit To Be Show	nts: nterview: 6/4 Requested: (2) [A] Perso	Art Unit: 2172 (2) (4) (7) Proposed onal (3) [] Visited: [] YES	Status of Ap Time: よ;00 deo Conference	plication: <u>A</u>	RECEIVED
Rej., Obj., etc) Fig. #s Art 1) Rej., 1-26			Issues To Be I	Discussed		
[] [] [] 3) [] [] [] 4) [] [] [] [] Continuation Sheet Attached Brief Description of Arguments to be Presented: Difference between known is recently claimed intention, principle. The use of symptom cloth in the present intention, principle. An interview was conducted on the above-identified application on NOTE: (his form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEF 713.01). (This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.			1 1103	Discussed	Agreed	Not Agreed
[] [] [] [] Continuation Sheet Attached Brief Description of Arguments to be Presented: Difference before known is recently claimed invention, principle. The set of sumption of the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPER 1713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.	1) Plej.	1-26	<u>kazemi</u>	[]	[]	[]
Continuation Sheet Attached Brief Description of Arguments to be Presented: Difference behaves leaders is resemble claimed introduce, pricularly an interview was conducted on the above-identified application on NOTE: his form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.	2)			[]	[]	[]
Continuation Sheet Attached The fearer before a feature of the above-identified application on INTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.	3)		*****	[]	[]	[]
Brief Description of Arguments to be Presented: Difference behavior to be presented: The very symptom clock in the protect is according for the protect in advance of the interview (see MPEF 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.	4)			[]	[]	E 1
Difference between known is present country claimed investion, principal. The use of symptom clots in the present country. An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.] Continuation Sho	eet Attached				
An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.	Brief Description of	Arguments to	be Presented:	the classical issues	nim p-lice	Mark.
An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPER 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.						
NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPER 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) is soon as possible.		<u> </u>	•		· · · · · · · · · · · · · · · · · · ·	
	NOTE: This form should be o 713.01). This application will I nterview. Therefore,	completed by app not be delayed fro , applicant is advi	licant and submitted to	o the examiner in ad plicant's failure to su	ıbmit a written	record of this

This collection of information is required by 37 CFR 1,133. The information is required to obtain or retain a bound by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 11 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22113-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.